Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis

Carroll, Lisa, Frazer, Ian H., Turner, Malcolm, Marwick, Thomas H. and Thomas, Ranjeny (2007) Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Research and Therapy, 9 2: R39.1-R39.8. doi:10.1186/ar2175


Author Carroll, Lisa
Frazer, Ian H.
Turner, Malcolm
Marwick, Thomas H.
Thomas, Ranjeny
Title Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis
Journal name Arthritis Research and Therapy   Check publisher's open access policy
ISSN 1465-9905
1478-6354
1478-6362
Publication date 2007-04-11
Year available 2007
Sub-type Article (original research)
DOI 10.1186/ar2175
Open Access Status DOI
Volume 9
Issue 2
Start page R39.1
End page R39.8
Total pages 8
Place of publication Liondon, United Kingdom
Publisher BioMed Central
Collection year 2008
Language eng
Abstract Patients with rheumatoid arthritis (RA) are at risk of excess mortality, predominantly owing to cardiovascular (CV) events. The receptor for advanced glycation end products (RAGE) has been implicated in the perpetuation of the chronic inflammatory response in vascular disease. A Gly82→Ser polymorphism in the RAGE gene, which is associated with enhanced RAGE signaling, is present more frequently in patients with RA than the general population. To investigate whether RAGE Gly82→Ser polymorphism is associated with CV events in RA, we examined CV events, CV risk factors, features of RA and RAGE Gly82→Ser polymorphism in 232 patients with RA attending a tertiary referral hospital. CV events, the duration and severity of RA, and risk factors for CV disease were determined using patient questionnaires, chart review, laboratory analysis and radiographs. DNA was typed for HLA–DRB1 genes and RAGE Gly82→Ser polymorphism. The RAGE Ser82 allele, which is in linkage disequilibrium with the RA susceptibility allele HLA–DRB1*0401, was carried by 20% of patients. More than 20% of the cohort had suffered a vascular event; a shorter duration of RA, but not the RAGE genotype, was significantly associated with CV events. However, a history of statin use was protective. Thus, the RAGE Ser82 allele, associated with enhanced RAGE signaling, does not predispose to CV events in RA. However, treatment of hyperlipidemia with statins reduces the probability of a CV event.
Keyword Rheumatology
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article number: R39

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 18 Apr 2008, 13:05:06 EST by Kylie Hengst on behalf of UQ Diamantina Institute